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Although by definition patients with adrenal incidentalomas
(AI) do not have evident clinical syndromes, they may fre-
quently suffer from subclinical hypercortisolism (SH). This is
of some importance because of evidence that SH may lead to
clinical complications, including bone loss. Thus, the under-
standing of bone involvement due to SH may be extremely
important in the management of AI. Unfortunately, the avail-
able data on bone mineral density (BMD) in AI patients come
from cross-sectional studies, which, to further complicate our
understanding, are also conflicting, probably due to a differ-
ent selection of patients and/or the variability in cortisol se-
cretion (CS) often described in AI. To gain further insight
about this topic, we performed a longitudinal study evaluat-
ing the rate of spinal and femoral bone loss levels in 24 females
with AI.
AI subjects were subdivided in two groups on the basis of
the median of urinary cortisol secretion (UFC): group I (n 12;
UFC, <140.4 nmol/24 h) and group II (n  12; UFC, >140.4
nmol/24 h). Spinal BMD was measured by both single energy
quantitative computed tomography (L1–L4) and dual energy
x-ray absorptiometry (DXA; L2–L4), and femoral BMD was
determined by DXA. Bone loss rate was expressed as the
change in z-score per yr.
The spinal bone loss rate was higher (P < 0.005) in group II
than in group I when measured by both quantitative com-
puted tomography (0.19  0.14 vs. 0.00  0.15) and DXA
(0.19 0.17 vs. 0.00 0.11). Moreover, CS and spinal bone loss
rate were significantly correlated when patients were con-
sidered together.
In conclusion, our data show that 1) AI patients with higher
CS have increased lumbar trabecular bone loss rate than
those with lower CS; and 2) the degree of spinal bone loss rate
is related to the degree of CS. Thus, lumbar spine (LS) BMD
has to be evaluated for well balanced decision-making on the
treatment of choice for AI female patients. (J Clin Endocrinol
Metab 86: 5337–5341, 2001)
IN THE LAST years incidentally discovered adrenalmasses [adrenal incidentalomas (AI)] have been detected
with increasing frequency due to the widespread use of
abdominal imaging techniques (1–4). Although by definition
AI patients do not show evident clinical syndromes, some of
these subjects may show a certain degree of cortisol hyper-
secretion, commonly called subclinical hypercortisolism
(SH) (5–13). It is still not clear whether SH may lead to clinical
complications, including osteoporosis; the knowledge of
bone involvement, if any, in AI may be extremely important
in the management of these patients.
While it is well known that overt glucocorticoid excess
leads to osteoporosis (14, 15), data on bone involvement in
AI patients with SH are conflicting. In fact, previous data
suggesting that SH in AI patients may lead to alteration of
bone metabolism (16) and bone loss (17) have not been con-
firmed by other reports (18, 19).
To gain further insight about this topic, a longitudinal
study of 24 female AI patients with various degrees of cor-
tisol secretion (CS) was performed, evaluating spine and
femoral bone mineral density (BMD) at baseline and after an
average of 29.6 months of follow-up. Only female patients
were studied to avoid the confounding factor of the possible
gender-dependent effect of high CS on BMD (20).
Subjects qnd Methods
Subjects
Twenty-four consecutive female patients with AI were longitudinally
studied at baseline and after variable follow-up periods (Table 1). Fifteen
of these subjects were previously enrolled in a cross-sectional study (17).
Diagnosis of AI was made on the basis of 1) unilateral adrenal mass
detected during noninvasive methods of imaging of the abdomen per-
formed for unrelated diseases, and 2) lack of signs and/or symptoms of
hormonal hypersecretion.
Taking into account the changeability of hormonal secretion over
time, in each subject all hormonal data are reported as the mean of
multiple observations (i.e. at least two, at the beginning and the end of
follow-up). Data for biochemical markers of bone metabolism were
obtained at baseline. AI subjects were subdivided into two numerically
identical groups on the basis of urinary cortisol secretion (UFC): group
I (n 12) with UFC values less than 135.5 nmol/24 h, and group II (n
12) with UFC values greater than 145.4 nmol/24 h; the median value of
the entire cohort was 140.4 nmol/24 h.
No postmenopausal patients were within the first 4 yr after the last
menses. Age, years since menopause, body mass index, duration of
follow-up, and gonadal status were not different between the two
groups (Table 1a). Finally, all eugonadal patients had regular menses for
the entire period of the study. Furthermore, we subdivided our sample
also according to the commonly used criteria for defining SH: group
SH (n  17) and group SH (n  7). The diagnosis of SH was made
on the presence of two of the following three alterations in the pituitary-
adrenal axis: 1) increased UFC levels [193.1 nmol/24 h, which is the
cut-off of both our and international (21) normal reference values], 2)
Abbreviations: AI, Adrenal incidentalomas; BGP, bone GLA protein;
BMD, bone mineral density; Cr, creatinine; CS, cortisol secretion; ,
change; D-Pyr, deoxypyridinoline; DXA, dual energy x-ray absorpti-
ometry; F after Dex, serum cortisol levels after 1-mg overnight dexa-
methasone suppression test; FN, femoral neck; LS, lumbar spine; QCT,
quantitative computed tomography; SH, subclinical hypercortisolism;
UFC, urinary cortisol secretion.
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unsuppressed serum cortisol levels after a 1-mg overnight dexameth-
asone suppression test (F after Dex;82.8 nmol/liter), and 3) low ACTH
levels (2.2 pmol/liter). We did not observe any difference in age, years
since menopause, body mass index, or duration of follow-up between
groups SH and SH (Table 1b).
No subject had evidence of neoplastic disease. At computed tomog-
raphy, all lesions were homogeneous and hypodense and had regular
margins; these features are compatible with the diagnosis of adreno-
cortical adenoma (4). The diameters of incidentalomas were not different
between groups I and II at baseline (mean  sd, 2.4  1.3 vs. 2.1  0.8
cm; P  NS; range, 1.0–5.5 and 0.9–3.5 cm, respectively) and at the end
of follow-up (mean sd, 2.8 1.5 vs. 2.6 1.0 cm; PNS; range, 1.0–5.5
and 0.9–4.7 cm, respectively); similar results were observed after sub-
dividing patients into SH and SH [at baseline (mean sd), 2.3 1.2
vs. 2.1  0.8 cm (P  NS; range, 1.0–5.5) and 0.9–3.0 cm, respectively;
at the end of follow-up, 2.7 1.4 vs. 2.7 0.9 cm (PNS; range, 1.0–5.5
and 0.9–3.7 cm, respectively)].
Two patients (no. 3 and 6 from group I in Table 2), who displayed
diameters of AI greater than 4 cm, had previously refused surgery. Four
patients from group I (no. 3, 9, 11, and 12 in Table 2) and five patients
from group II (no. 2, 3, 6, 7, and 8 in Table 2) showed an increase in
diameter of AI greater than 20% with respect to baseline. The percent
increase in AI diameter was not different between groups I and II
(mean  sd, 13.7  18.9% vs. 18.5  16.8%; P  NS; range, 0–50% and
0–52.7%, respectively) and between groups SH and SH (mean sd,
14.9  17.8% vs. 18.9  18.1%; P  NS; range, 0–50% and 0–52.7%,
respectively).
Pheochromocytoma and aldosteronoma were excluded by appropri-
ate hormonal measurements (24-h urinary catecholamines, PRA and
aldosterone in the recumbent position and after 3 h of orthostatic
posture).
Premenopausal women were studied in the early follicular phase (d
3–7) of the menstrual cycle.
All subjects gave informed consent before the study. None of them
was given medications known to affect bone metabolism, including E
replacement therapy. In the last 3 yr all patients had been given 1 g/d
calcium and 880 IU/d vitamin D3, orally, to avoid bone metabolism
alterations due to possible subclinical vitamin D deficiency. Vertebral
fractures were excluded in all subjects by lateral x-ray of the spine.
Methods
In all subjects serum total calcium, phosphorous, and creatinine were
determined by a multichannel autoanalyzer to exclude concomitant
diseases that could affect bone metabolism. In all patients serum de-
terminations of ACTH (mean of three determinations at 20-min inter-
vals), cortisol, intact PTH, and bone GLA protein (BGP) levels were
performed at 0800 h, and total deoxypyridinoline (D-Pyr/Cr) levels
were measured in fasting spot urine, then corrected for creatinine ex-
cretion. Serum and urinary samples were collected and stored at 70 C
until assayed.
Cortisol and UFC levels (after dichloromethanol extraction) were
measured immunofluorimetrically by kits (TDX-FLX Abbott, GmbH,
Diagnostika, Wiesbaden-Delkenheim, Germany); serum ACTH levels
were measured by IRMA (BRAHMS Diagnostica GmbH, Berlin, Ger-
many). Serum intact PTH levels were measured by a two-site immu-
nochemiluminometric assay (Chiron Corp., East Walpole, MA). BGP
was assayed by IRMA for the intact molecule (ELSA-OST-NAT, Cis
Biointernational, Gif-sur-Yvette, France; intra- and interassay coeffi-
cients of variation, 3.8% and 4.7%, respectively), and D-Pyr/Cr was
assayed fluorometrically, after reverse phase HPLC, by kits from Bio-
Rad Laboratories, Inc. (Segrate, Italy; intra- and interassay coefficients
of variation, 6.6% and 12.3%, respectively).
BMD was evaluated at both axial and appendicular skeletal sites, as
previously described (22). Spinal BMD was measured by both single
energy quantitative computed tomography (QCT; L1–L4; Toshiba CT
Xpeed, Toshiba Medical Systems Division, Tokyo, Japan), which is able
to detect selectively trabecular true density (in vivo precision, 1.8%), and
dual energy x-ray absorptiometry (DXA; L2–L4; Norland XR-26, Nor-
land Instruments, Fort Atkinson, WI), which assesses the BMD of total
vertebral bodies (in vivo precision, 1.0%). BMD was also evaluated by
DXA at the femoral neck (FN; in vivo precision, 2.4%). Individual BMD
values were expressed as sd units (z-scores) in relation to reference
population of our center (23) and as the change in () z-scores per yr
between baseline and the end of follow-up.
Statistical analysis
The results are expressed as the mean  sd. For each variable, nor-
mality of distribution was tested by the W statistic of Shapiro-Wilk.
Comparison between groups of patients was performed using unpaired
t test or Mann-Whitney U test as appropriate. To compare different
subgroups (eumenorrheic and postmenopausal patients in groups I and
II), two-way ANOVA and Student-Newman-Keuls post-hoc analysis
were performed. Fisher’s exact test was used to evaluate the difference
in the ratio of eu-/hypogonadal patients in the SH and SH groups.
The associations between variables were tested by either Pearson or
Spearman correlation, as appropriate. P  0.05 was considered
significant.
Results
Hormonal and BMD data for patients in groups I and II are
summarized in Table 2. By selection criterion, UFC levels
TABLE 1a. Clinical characteristics of all, group I, and group II patients
All (n  24) Group I (n  12) Group II (n  12)
Age at baseline (yr) 54.9  13.1 (26–77) 55.7  13.0 (38–77) 54.1  13.7 (26–72)
YSM at baseline 13.8  6.7 (70–92) 15.5  7.2 (6–27) 12  6.2 (6–22)
Pre-/postmenopause 8/16 4/8 4/8
Months of follow-up 29.6  14.1 (12–61) 29.0  13.6 (15–61) 30.3  15.3 (12–60)
BMI (kg/m2) 28.0  3.9 (22.4–37.2) 28.4  4.2 (23.1–35.0) 27.6  3.8 (22.4–37.2)
Data are expressed as the mean  SD (range). Patients are presented either all together (All) or subdivided on the basis of the median of
crescent UFC levels with group I including the first 12 patients, and group B including patients 13–24. YSM, Years since menopause; BMI,
body mass index at baseline. No differences were found between the groups I and II for each variable.
TABLE 1b. Clinical characteristics of group SH and group SH patients
Group SH (n  17) Group SH (n  7)
Age at baseline (yr) 56.0  11.8 (38–77) 42.4  16.7 (26–72)
YSM at baseline 13.9  7.15 (6–27) 13.3  6.2 (8–22)
Pre-/postmenopause 5/12 3/4
Months of follow-up 31.6  16.2 (12–61) 24.8  5.4 (19–33)
BMI (kg/m2) 28.5  4.5 (22.4–37.2) 26.8  2.0 (23.1–29.4)
Data are expressed as the mean SD (range). Patients are subdivided in two groups according with the absence (group SH) or the presence
(group SH) of subclinical hypercortisolism (see Subjects and Methods). YSM, Years since menopause; BMI, body mass index at baseline. No
differences were found between the two groups for each variable.
5338 J Clin Endocrinol Metab, November 2001, 86(11):5337–5341 Chiodini et al. • Adrenal Incidentalomas and Bone Loss Rate
 on January 3, 2006 jcem.endojournals.orgDownloaded from 
were significantly higher in group I. ACTH and F after Dex
levels were significantly different, being respectively lower
and higher in group II than in group I (Table 2). PTH levels
were not different between the two groups.
The mean z-scores per yr of lumbar BMD measured by
both QCT and DXA were significantly lower in group II than
in group I (Table 2). The mean z-score per yr of FN BMD
in group II tended to be lower, although not statistically (P
0.12), than that in group I subjects.
When comparing by ANOVA, mean DXA and QCT z-
scores per yr of eu- and hypogonadal patients from group I
(eugonadal, n  4; hypogonadal, n  8) and group II (eugo-
nadal, n 4; hypogonadal, n 8), no statistically significant
difference was observed after allowing for the difference in
CS, whereas the difference between mean DXA and QCT
z-scores per yr in group I compared with group II was
confirmed after allowing for the difference in gonadal status.
Mean values of BGP and D-Pyr/Cr at baseline were not
different between groups I and II [BGP, 1.48  0.45 pmol/
liter (range, 0.89–2.34) vs. 1.24  0.44 pmol/liter (range,
0.79–2.13; P  NS); D-Pyr, 22.3  9.0 pmol/pmol (range,
11.1–35.5) vs. 19.9  6.4 pmol/pmol (range, 11.7–29.5; P 
NS), respectively].
As far as the correlations between BMD and markers of
disease activity are concerned, in the whole group of patients
a significant correlation was found between QCT  z-scores
per yr and UFC (r 0.52; P 0.01), F after Dex (r 0.49; P
0.02), and ACTH (r  0.44; P  0.05) and between DXA
 z-scores per yr and UFC (r  0.47; P  0.05).
Although the normal distribution of UFC levels suggests
that CS in AI is a continuum trait in our cohort, we reeval-
uated our data by categorizing CS on the basis of commonly
used criteria for SH diagnosis (13). No difference was found
between SH and SH patients in gonadal status (Table 2).
Hormonal and BMD data from groups SH and SH are
summarized in Table 3. According to the selection criteria,
UFC, F after Dex, and ACTH levels were different between
the two groups, being respectively higher (UFC and F after
Dex) and lower (ACTH) in group SH compared with group
SH. Mean z-scores at baseline and mean z-scores per yr
of lumbar BMD measured by both QCT and DXA were
significantly lower in group SH than in group SH,
whereas mean z-scores at baseline and mean z-scores per
yr of FN BMD were not significantly different between the
two groups. PTH levels tended to be higher in group SH
than in group SH, although the difference was not statis-
tically significant (P 0.06; Table 3). Finally, mean values of
BGP and D-Pyr at baseline were not different between group
SH and group SH [BGP (mean  sd), 1.41  0.45 pmol/
liter (range, 0.82–1.99) vs. 1.22 0.41 pmol/liter (range 0.79–
2.34; PNS); D-Pyr/Cr (mean sd), 22.1 8.22 pmol/pmol
TABLE 2. Gonadal status, biochemical indexes of adrenal function, and BMD at different skeletal sites of group I and group II patients
Patient no. YSM UFC ACTH F after dex SH DXA QCT FN PTH
Group I
1 10 55.2 2.2 55.2  0.03 0.03 0.03 53.0
2 20 64.6 2.6 46.9  0.06 0.13 0.09 57.5
3 14 91.9 3.0 22.1  0.02 0.04 0.03 25.1
4 11 101.3 1.9 55.2  0.07 0.13 0.41 70.1
5 23 102.4 2.4 41.4  0.02 0.26 0.03 47.8
6 4 105.4 5.3 33.1  0.07 0.03 0.08 33.9
7 27 110.4 2.6 55.2  0.03 0.03 0.04 45.0
8 13 114.5 5.6 46.9  0.06 0.07 0.09 59.9
9 0 130.8 5.3 66.2  0.15 0.00 0.06 31.5
10 0 132.2 1.2 22.1  0.04 0.20 0.10 32.8
11 0 135.0 2.6 49.7  0.15 0.18 0.22 39.8
12 0 135.5 2.8 38.6  0.25 0.27 0.11 57.6
Mean  SD 106.5  26.2 3.1  1.4 44.2  13.8 0.00  0.11 0.00  0.15 0.04  0.15 45.8  13.7
Group II
1 4 145.4 1.4 60.7  0.25 0.14 0.04 57.3
2 21 162.3 5.4 46.9  0.08 0.13 0.08 43.7
3 0 175.0 2.2 38.6  0.05 0.03 0.08 32.3
4 10 177.5 2.0 82.8  0.45 0.15 0.29 64.3
5 9 190.4 1.9 58.0  0.02 0.24 0.01 38.4
6 8 196.0 0.8 74.5  0.39 0.29 0.04 55.3
7 0 200.9 1.7 44.2  0.25 0.28 0.01 52.5
8 7 220.8 2.6 41.4  0.24 0.23 0.03 55.0
9 13 223.8 1.2 88.3  0.30 0.14 0.03 90.0
10 0 248.7 2.2 35.9  0.01 0.08 0.21 38.0
11 22 267.7 1.5 138.0  0.30 0.31 0.03 50.0
12 0 297.5 1.9 77.3  0.04 0.46 0.08 53.3
Mean  SD 208.9  45.0 2.1  1.1a 65.1  30.4a 0.19  0.17b 0.19  0.14b 0.03  0.13 51.6  11.4
Data are expressed as the mean  SD. Group I, Patients 1–12; group II, patients 13–24, ordered on the basis of crescent UFC levels. YSM,
Years since menopause at baseline; UFC, urinary free cortisol (normal values,193.1 nmol/24 h); ACTH, mean of three determinations at 0800 h
(normal values, 2.2 pmol/liter); F after Dex, Serum cortisol at 0800 h after 1 mg overnight dexamethasone (normal values, 82.8 nmol/liter);
PTH, normal values, 10–70 ng/liter; SH, subclinical hypercortisolism (, absent; , present; see Subjects and Methods); DXA, change per yr
of z-values of lumbar vertebral integral spine L2–L4 bone mineral density; QCT, change per yr of z-values of lumbar trabecular vertebral spine
L1–L4 bone mineral density; FN, change per yr of z-values of femoral neck bone mineral density.
a P  0.05 vs. group I.
b P  0.005 vs. group I.
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(range, 11.1–35.5) vs. 18.6  6.31 pmol/pmol (range, 11.7–
28.0; P  NS), respectively].
Discussion
This study was aimed at understanding whether different
degrees of CS in AI patients could affect bone tissue. For this
purpose we performed a longitudinal study on 24 female
patients quantitatively ordered on the basis of the median of
UFC values into groups of 12 patients with lower CS (group
I) and 12 patients with higher CS (group II). The 2 groups of
patients also had different ACTH and F after Dex levels, thus
confirming that they were truly different as far as the degree
of CS was concerned.
Our data show that AI patients with higher levels of CS
have higher bone loss rates, and these two parameters are
significantly correlated in the whole cohort studied. This
finding is compatible with and reinforces our previous cross-
sectional data (17), showing a reduction in BMD in AI pa-
tients with SH compared with those without SH. In contrast,
no BMD reduction in AI patients with SH has been reported
in other cross-sectional studies (18, 19). These discrepancies
among cross-sectional studies may be due to different causes.
Firstly, different cut-off values for the diagnosis of SH may
justify the different results. In fact, it is still not clear which
are the best hormonal tests and their best cut-off values to
identify AI patients with SH (11, 24). Secondly, previous
negative studies involved both male and female subjects (18,
19), at variance with our antecedent (17) and present inves-
tigations, in which only females were evaluated. In fact, a
gender-dependent sensitivity of bone tissue to glucocorticoid
excess has been reported (20), with males being much less
sensitive than females. This may well explain the lack of
glucocorticoid effect in those studies comprising both male
and female patients. Finally, as bone mass is the result of
different genetic (25), metabolic (26), and hormonal (27) fac-
tors, and cortisol hypersecretion, if present, is subtle in AI
patients, it is possible that a cross-sectional evaluation in a
small series may not always be able to detect small differ-
ences in a wide range of BMD distributions. To overcome the
two latter potential pitfalls, we designed the present longi-
tudinal study carried out only in female patients. The results
obtained clearly demonstrated that BMD loss is increased in
AI female patients with higher CS.
Patients with higher cortisol secretion had higher trabec-
ular bone loss rate as measured at LS regardless of gonadal
status, as suggested by ANOVA. These data were indirectly
confirmed by the correlation between disease activity pa-
rameters (UFC, F after Dex, ACTH) and rate of trabecular
bone loss at LS. A similar, although not significant, difference
was found at FN. This is partly at variance with our previous
cross-sectional study, in which a statistically significant re-
duction of bone mass was observed at both LS and FN. Even
if the two studies are not comparable because of the different
designs, we believe that this seeming discrepancy may be
due to the lower disease activity of AI subjects in this in-
vestigation compared with those in the previous one (17), as
indicated by lower mean values of UFC in SH patients in the
present report (230.5 vs. 332.9 nmol/24 h). Finally, we found
that PTH levels were higher, although not statistically so, in
patients with SH compared to those without SH. This is in
line with previous reports by us (17) and others (18) and
suggests the state of altered bone turnover in patients with
AI and SH. Nevertheless, at variance with our previous study
in which we found comparable D-Pyr/Cr levels and reduced
BGP levels in SH compared with SH patients (17), in the
present investigation markers of bone turnover (BGP and
D-Pyr/Cr) at baseline were comparable between SH and
SH patients. Although entirely speculative, we believe that
this discrepancy may be due to the lower disease activity of
AI subjects with SH in this investigation compared with
those in the previous study (17).
In conclusion, our data 1) confirm our previous observa-
tion that AI patients with higher CS have reduced lumbar
trabecular BMD; 2) show that among AI patients, those with
higher CS have increased lumbar trabecular bone loss rate;
and 3) show that the degree of spinal bone loss rate is directly
related to the degree of CS. Based on these results, the need
for BMD evaluation at the spine in all female AI patients is
strongly suggested. In fact, the knowledge of reduced bone
mass may help in making decisions about the need for sur-
gical excision in AI tumors smaller than 4 cm (4, 7).
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TABLE 3. Biochemical indexes of adrenal function and BMD z-
scores at baseline and z-scores per yr at different skeletal sites in
group SH and group SH patients
Group SH (n  17) Group SH (n  7)
UFC 127.8  42.8 230.5  43.1a
ACTH 2.97  1.4 1.6  0.5b
F-after Dex 44.1  13.8 77.3  33.1c
DXA 0.64  1.3 0.67  0.32c
DXA 0.03  0.13 0.25  0.16b
QCT 0.26  0.98 0.71  0.63c
QCT 0.04  0.15 0.22  0.17c
FN 0.35  1.0 0.37  0.60
FN 0.03  0.13 0.02  0.15
PTH 45.6  12.5 56.2  10.2
Data are expressed as the mean  SD. Patients are subdivided in
two groups according with the absence (group SH) or presence (group
SH) of subclinical hypercortisolism (see Subjects and Methods).
UFC, Urinary free cortisol (normal values,193.1 nmol/24 h); ACTH,
mean of three determinations at 0800 h (normal values, 2.2 pmol/
liter); F after Dex, serum cortisol at 0800 h after overnight 1 mg
dexamethasone (normal values, 82.8 nmol/liter); PTH, normal val-
ues, 10–70 ng/liter; DXA, DXA, mean z-scores at baseline and mean
z-scores per yr, respectively, of lumbar vertebral integral spine
L2–L4 bone mineral density. QCT, QCT, mean z-scores at baseline
and mean z-scores per yr, respectively, of lumbar trabecular verte-
bral spine L1–L4 bone mineral density; FN, FN, mean z-scores at
baseline and meanz-scores per yr, respectively, of femoral neck bone
mineral density.
a P  0.0001.
b P  0.01.
c P  0.05.
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